Strain Data Sheet

RBRC10043

Strain Information

Image
BRC No.RBRC10043
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.Cg-Mapt<tm1.1(MAPT)Tcs> App<tm3(NL-G-F)Tcs>
Former Common name
H-2 Haplotype
ES Cell line
Background strain
Appearance
Strain development
Strain description
Colony maintenance
References
Recent Advances in the Modeling of Alzheimer's Disease.
Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, Kaori Sato, Risa Takamura, Kenichi Nagata, Satoshi Tsubuki, Toshio Ohshima, Atsushi Yoshiki, Kenya Sato, Wakako Kumita, Erika Sasaki, Shinobu Kitazume, Per Nilsson, Bengt Winblad, Takashi Saito, Nobuhisa Iwata, Takaomi C Saido
Front. Neurosci., 16:807473 (2022). 35431779

Single App knock-in mouse models of Alzheimer's disease.
Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido T C
Nat. Neurosci., 17(5):661-663 (2014). 24728269

Tau binding protein CAPON induces tau aggregation and neurodegeneration.
Hashimoto S, Matsuba Y, Kamano N, Mihira N, Sahara N, Takano J, Muramatsu S I, Saido T C, Saito T
Nat. Commun., 10(1):2394 (2019). 31160584

Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation.
Saito T, Mihira N, Matsuba Y, Sasaguri H, Hashimoto S, Narasimhan S, Zhang B, Murayama S, Higuchi M, Lee V M Y, Trojanowski J Q, Saido T C
J. Biol. Chem., 294(34):12754-12765 (2019). 31273083

Health Report

Examination Date / Room / Rack2024/08/26Room:4-BRack:B
2024/05/27Room:4-BRack:B
2024/02/26Room:4-BRack:B
2023/11/27Room:4-BRack:B
2023/10/10Room:3-ARack:B
2023/08/28Room:4-BRack:B
2023/07/10Room:3-ARack:B
2023/04/10Room:3-ARack:B
2023/01/10Room:3-ARack:B

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Frtyeast FRT (flippase recombination target) site11Frt
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • MAPTmicrotubule-associated protein tau (human)11MAPT
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • Maptmicrotubule-associated protein tau11Mapttargeted mutation 1.1, Takaomi C. Saido
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • loxPphage P1 loxP11loxP
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • Appamyloid beta precursor protein16Apptargeted mutation 3, Takaomi C. Saido
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • Frtyeast FRT (flippase recombination target) site16Frt
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • loxPphage P1 loxP16loxP
  • Alzheimer disease type 1(MedGEN)

  • Alzheimer disease(DisGeNET)

  • cerebral amyloid angiopathy, APP-related(MedGEN)
  • more 5 Diseases
  • frontotemporal dementia(DisGeNET, MedGEN)

  • late-onset Parkinson disease(MedGEN)

  • Pick disease(DisGeNET, MedGEN)

  • progressive supranuclear palsy-parkinsonism syndrome(MedGEN)

  • supranuclear palsy, progressive, 1(MedGEN)
  • Phenotype

    Annotation by Mammalian phenotyhpe ontology
    Detailed phenotype data

    Ordering Information

    Donor DNAhuman MAPT genomic DNA, yeast FRT (flipase recombination target) sites, Phage P1 loxP sites, mouse Mapt genomic DNA, mouse App genomic DNA (mutant type)
    Research applicationCre/loxP system
    FLP/frt system
    Mouse Models for Human Disease
    Specific Term and ConditionsThe BIOLOGICAL RESOURCE is the property of the RIKEN (The Institute of Physical and Chemical Research). RECIPIENT agrees to acknowledge Shoko HASHIMOTO, Takashi SAITO and Takaomi C. SAIDO in an acknowledgement section. RECIPIENT also agrees to cite Nature Neuroscience 17, 661-663 (2014), Nature Communications 10: 2394 (2019) and Journal of Biological Chemistry, 294: 12754-12765 (2019) in all publications obtained using BIOLOGICAL RESOURCE. RECIPIENT agrees to acknowledge DEPOSITOR in all oral presentations and written publications as related to the BIOLOGICAL RESOURCE. RECIPIENT shall keep confidential any or all information marked CONFIDENTIAL that is received from DEPOSITOR and related to the BIOLOGICAL RESOURCE including oral discussions if they are reduced to writing within thirty (30) days and are marked "CONFIDENTIAL". For-profit organizations must contact the DEPOSITOR (takaomi.saido@riken.jp) for a licensing contract. If any invention is conceived and reduced to practice by RECIPIENT in the performance of the Research Plan involving the BIOLOGICAL RESOURCE during the term of this MTA, RECIPIENT agrees to promptly inform the invention to DEPOSITOR and the parties will consult each other to determine inventorship and ownership of the invention based on the respective parties contribution to the invention, before filing an application for a patent. In the case of a jointly owned application, the parties will separately enter into a joint application agreement including the sharing of ownership, patent costs and licensing income, as well as the responsible party for the application procedures etc.
    DepositorTakaomi C. Saido (RIKEN CBS)
    Strain Statusan icon for Live miceLive mice
    an icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityCryopreserved sperm (within 1 month)
    Cryopreserved embryos (within 1 month)
    Live mouse (3 to 6 months)
    Additional Info.Necessary documents for ordering:
    1. Order form (Japanese / English)
    2. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    3. Acceptance of responsibility for living modified organism (Japanese / English)
    Lab HP (Japanese/English)
    Genotyping protocol -PCR-

    BRC mice in Publications

    Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, Kaori Sato, Risa Takamura, Kenichi Nagata, Satoshi Tsubuki, Toshio Ohshima, Atsushi Yoshiki, Kenya Sato, Wakako Kumita, Erika Sasaki, Shinobu Kitazume, Per Nilsson, Bengt Winblad, Takashi Saito, Nobuhisa Iwata, Takaomi C. Saido
    Recent Advances in the Modeling of Alzheimer’s Disease
    Frontiers Neuroscience 16 (2022) 35431779